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Abstract
Background: Germline mutations in RET are responsible for multiple endocrine neoplasia type 2 (MEN2), an autosomal
dominantly inherited cancer syndrome that is characterized by medullary thyroid carcinoma (MTC), pheochromocytoma, and
parathyroid hyperplasia/adenoma. Recent studies suggest a "second hit" mechanism resulting in amplification of mutant RET.
Somatic VHL gene alterations are implicated in the pathogenesis of MEN2 pheochromocytomas. We hypothesized that somatic
VHL gene alterations are also important in the pathogenesis of MEN2-associated MTC.
Methods: We analyzed 6 MTCs and 1 C-cell hyperplasia (CCH) specimen from 7 patients with MEN2A and RET germline
mutations in codons 609, 618, 620, or 634, using microdissection, microsatellite analysis, phosphorimage densitometry, and VHL
mutation analysis.
Results: First, we searched for allelic imbalance between mutant and wild-type RET by using the polymorphic markers D10S677,
D10S1239, and RET on thyroid tissue from these patients. Evidence for RET amplification by this technique could be
demonstrated in 3 of 6 MTCs. We then performed LOH analysis using D3S1038 and D3S1110 which map to the VHL gene locus
at 3p25/26. VHL gene deletion was present in 3 MTCs. These 3 MTCs also had an allelic imbalance between mutant and wild-
type RET. Mutation analysis of the VHL gene showed a somatic frameshift mutation in 1 MTC that also demonstrated LOH at
3p25/26. In the 2 other MTCs with allelic imbalance of RET and somatic VHL gene deletion, no somatic VHL mutation could be
detected. The CCH specimen did neither reveal RET imbalance nor somatic VHL gene alterations.
Conclusion: These data suggest that a RET germline mutation is necessary for development of CCH, that allelic imbalance
between mutant and wild-type RET may set off tumorigenesis, and that somatic VHL gene alterations may not play a major role
in tumorigenesis of MEN2A-associated MTC.
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Medullary thyroid carcinoma (MTC) develops from the
parafollicular C cells in the thyroid gland and occurs spo-
radically as well as in the hereditary syndrome multiple
endocrine neoplasia type 2 (MEN2). The gene responsible
for MEN2 is the RET protooncogene, located at chromo-
some 10q11.2 [1,2]. Patients with germline mutations in
RET invariably develop MTC, although there are some
patients with RET germline mutations who have lived
beyond age 70 without MTC [3,4]. Therefore, patients
with germline mutations in RET usually are divided into
different risk groups (low, intermediate, and high risk for
developing MTC). So-called low-risk or level I mutations
include those at codons 609, 768, 790, 791, 804, and 891
[1,5-8]. Hyperplasia of the parafollicular C cells has been
regarded as the precursor lesion for MTC [9,10]. Accumu-
lating evidence suggests that a 'second hit' or additional
genetic events may be required to set off tumorigenesis in
susceptible cells of patients with RET germline mutations.
An allelic imbalance between mutant and wild-type RET
may represent the decisive step of tumorigenesis for MTC
and pheochromocytoma [11-15]. Somatic VHL gene alter-
ations are implicated in the pathogenesis of MEN2-associ-
ated pheochromocytomas, possibly through
accumulation of RET protein [16]. Therefore, we hypoth-
esized that somatic VHL gene alterations may also play a
role in the pathogenesis of MEN2-associated MTC.
Methods
Patients and tissues
Seven patients with MEN2A and RET germline mutations
in codons 609 (4 patients, Leipzig), 618 (1 patient, St.
Louis), 620 (1 patient, St. Louis), or 634 (1 patient, NIH)
underwent total thyroidectomy at the Washington Uni-
versity in St. Louis, MO, the National Institutes of Health
in Bethesda, and the University of Leipzig, Germany. In 6
patients, MTC was diagnosed; 1 patient had C cell hyper-
plasia (Tables 1 and 2). None of the patients had clinical
evidence for VHL syndrome and was analyzed for germ-
line mutations in the VHL gene.
Two specimens (cases 1 and 2 in Table 1) were previously
analyzed for imbalance of the mutant and wild-type RET
allele (see Ref. [12]).
Frozen or paraffin-embedded tissue was microdissected
and analyzed for loss of heterozygosity (LOH) by poly-
morphic markers mapping to the VHL gene locus, as pre-
viously described [16].
Tissue was obtained from these 7 patients under an Inter-
nal Review Board (IRB)-approved protocol at the
National Institutes of Health. All of them had MEN 2A
with a germline mutation in RET. Blood was drawn for
DNA extraction. Thyroid specimens including MTC were
removed at the time of surgery and frozen at -80°C. DNA
was extracted from lymphoblasts and tumor tissue by
standard methods.
Six-micron sections were obtained from frozen tumor and
briefly stained with hematoxylin and eosin (H & E). If no
frozen tumor was available, paraffin-embedded tissue was
prepared for microdissection. Under direct light micro-
scopic visualization using a 30-gauge needle, a modified
microdissection procedure was performed, as previously
described [17]. In all cases, we obtained also samples of
nontumor control tissue from the same slides.
Allelic imbalance of the RET gene locus and loss of 
heterozygosity of the VHL gene locus
We performed imbalance analyses of RET, using polymor-
phic markers/primers D10S677, D10S1239, and RET for
the RET locus, and loss of heterozygosity studies using
markers D3S1038 and D3S1110 which map to the VHL
gene locus 3p25/26 in the presence of [alpha-32P] dCTP
(0.1 µCi/µl) (Dupont). PCR conditions using AmpliTaq
Gold DNA polymerase (Perkin Elmer Roche) in a Hybaid
Omnigene thermal cycler were as follows: initial denatur-
ation at 95°C for 10 min, then 35 cycles, each with 1 min
of denaturation at 95°C, 1 min of annealing at 55°C for
RET markers, at 60°C for VHL markers, and 1 min of
Table 1: Somatic VHL gene deletion and mutation in MEN 2A-associated medullary thyroid carcinomas/CCH with germline mutations 
of RET
Case RET germline Mutation LOH at the VHL locus Somatic VHL Mutation Allelic imbalance of RET
1 Codon 620 TGC/CGC Yes del C nt 389 Exon 1 Yes (D10S677)
2 Codon 618 TGC/AGC Yes No Yes (D10S677)
3 Codon 609 TGC/CGC Yes N/A Yes (D10S677)
4 Codon 609 TGC/CGC No N/A No
5 Codon 609 TGC/CGC No No No
6 Codon 609 TGC/CGC No No No
7 (CCH) Codon 634 TGC/CGC No No No
N/A, not availablePage 2 of 7
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sion at 72°C for 10 min. The amplicons were resolved on
a 6% polyacrylamide gel. Gels were dried and exposed to
Kodak XAR film. All PCR reactions were performed in trip-
licate.
VHL gene mutation analysis
Exons 1–3 of the VHL gene were amplified from genomic
DNA using polymerase chain reaction conditions
described elsewhere [18]. Mutation scanning by confor-
mation sensitive gel electrophoresis (CSGE) was per-
formed on the PCR products as described by Ganguly et al.
[19]. DNA sequence analysis was performed using a cycle
sequencing kit with dye-labeled terminators (PE
Advanced Biosystems, Inc., Foster City, CA). Sequences
were analyzed on an ABI 377 automated DNA sequencer.
Results
We studied 6 medullary thyroid carcinomas and 1 C-cell
hyperplasia specimen from 7 patients with MEN 2A and
known RET germline mutations for allelic imbalance at
the RET locus and for somatic genetic alterations at the
VHL gene locus at 3p25/26 including LOH and mutations
(Table 1). Allelic imbalance between the mutant and
wild-type RET allele could be demonstrated in 3 MTCs
(Fig. 1). The same 3 tumors also had LOH of the VHL gene
locus (Fig. 2).
To further investigate whether inactivation of the VHL
tumor suppressor gene plays a role in tumorigenesis of
MEN 2A-related MTC, we performed mutation analysis of
the VHL gene and found mutations in at least 1 of the 7 C-
cell specimens (Figs. 3 and 4, Table 1). Mutation analysis
of the VHL gene showed a frameshift mutation in 1 MTC.
LOH analysis of the VHL gene locus of 3 cases of MEN 2A-related MTCs wit  marker D3S1038 or D3S1110Figure 2
LOH analysis of the VHL gene locus of 3 cases of MEN 
2A-related MTCs with marker D3S1038 or D3S1110. 
All cases show loss of one allele in microdissected tumor tis-
sue (T), whereas heterozygosity is retained in normal non-
neoplastic tissue (N). Arrows indicate the 2 VHL alleles.
Table 2: Clinical features
Case RET germline Mutation Plasma calcitonin (pg/
ml, normal: < 100)
Age at thyroidectomy Pheochromo-cytoma/HPT
1 Codon 620 TGC/CGC N/A N/A N/A
2 Codon 618 TGC/AGC N/A N/A N/A
3 Codon 609 TGC/CGC 118 40 y No
4 Codon 609 TGC/CGC 120 41 y No, but HTN
5 Codon 609 TGC/CGC 563 43 y No, but HTN
6 Codon 609 TGC/CGC 787 44 y Unilateral pheo
7 (CCH) Codon 634 TGC/CGC N/A 25 y No
N/A, not available; HTN, hypertension
Allelic imbalance of mutant and wild-type RET in one repre-sentative c se (case 3, T ble 1) of MEN2A-associated medul-lary thyroid car ino aFigure 1
Allelic imbalance of mutant and wild-type RET in one 
representative case (case 3, Table 1) of MEN2A-asso-
ciated medullary thyroid carcinoma. T3, tumor from 
case 3; N, normal tissue; D10S677, polymorphic marker. The 
arrows indicate the 2 RET alleles.Page 3 of 7
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gene locus (case 1 in Table 1). Another tumor (case 2) had
LOH at the RET and VHL gene locus but no somatic VHL
mutation. In cases 3 and 4, the mutation analysis for VHL
could not be completely performed (exon 1 was analyzed
and negative for mutations; exons 2 and 3 could not be
analyzed) because of technical problems and no further
DNA left. Cases 5 and 6 (MTC) as well as case 7 (CCH)
had neither LOH at RET or VHL nor somatic mutations of
VHL.
Discussion
In this study, we show that somatic VHL mutation and
deletion are involved in tumor progression rather than
tumor initiation of MEN 2A-related MTC. In both spo-
radic and familial forms of MTC, allelic losses at 1p, 3, 4,
9q, 10q, 13q, and 22q have been reported [20-24]. Spe-
cific tumor suppressor genes or oncogenes at these chro-
mosomal loci, however, have rarely been analyzed.
In sporadic pheochromocytomas, somatic mutations of
VHL or RET are found in less than 10% of tumors, suggest-
ing a possible role in tumorigenesis, whereas the preva-
lence and role of such mutations in hereditary
pheochromocytomas such as those occurring in MEN 2 is
not known. In a recent study, we detected inactivating
somatic mutations of VHL and LOH at 3p25/26 in several
MEN 2A-related pheochromocytomas [16]. In all of these
MEN 2A-associated pheochromocytomas as well as in the
present study of thyroid C cell specimens, regular wild-
type VHL alleles were detected in normal control tissue
confirming the presence of two wild-type alleles and
excluding the presence of VHL disease.
VHL disease consists of a variety of tumors including phe-
ochromocytoma [25,26]. However, MTC is not part of
VHL syndrome, although MTC was found (likely coinci-
dentally) in 2 patients with VHL germline mutation [27].
Mutations in the VHL gene lead to constitutive expression
of many hypoxia-inducible genes, in part related to
increasing levels of hypoxia-inducible transcription factor
(HIF) 1-alpha which in normal cells is rapidly ubiquiti-
nated and degraded [28]. VHL protein, a ubiquitinase
adapter, plays a role in cell-cycle control, differentiation,
extracellular matrix formation and turnover, and angio-
genesis. Therefore, mutations in VHL may lead to an
absent or reduced VHL protein function with reduced deg-
radation of proteins including RET protein. In addition to
other events, RET protein accumulation secondary to
absent or reduced VHL protein, may then cause further
transformation of selected parafollicular C-cells.
Normal sequence of the VHL gene, portion of exon 1, com-pared to muta t sequence in figur  3Figure 4
Normal sequence of the VHL gene, portion of exon 1, com-
pared to mutant sequence in figure 3.
Somatic mutation of the VHL gene in MEN2-associated MTCFigure 3
Somatic mutation of the VHL gene in MEN2-associ-
ated MTC. Portion of the sequence of exon 1 from case 1 
demonstrating a deletion of a single base (del C) at nucle-
otide 389 of the VHL gene in one allele at the position indi-
cated by the arrow. This mutation would result in a shift in 
the translational frame of the encoded mRNA from codon 59 
to a premature stop codon at position 66. Exons 1–3 of the 
VHL gene were amplified from genomic DNA using polymer-
ase chain reaction conditions described elsewhere (Stolle et 
al.,1998). Mutation scanning by conformation sensitive gel 
electrophoresis (CSGE) was performed on the PCR prod-
ucts obtained using PCR conditions described by Ganguly et 
al., 1993. DNA sequence analysis was performed using a 
cycle sequencing kit with dye-labeled terminators (PE 
Advanced Biosystems, Inc., Foster City, CA). Sequences 
were analyzed on an ABI 377 automated DNA sequencer.Page 4 of 7
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in the wild-type VHL allele, is necessary for initiation of
tumor growth in patients with VHL germline mutations, it
may not be sufficient [26,29,30]. Similarly, in patients
with MEN2, a RET germline mutation is necessary for for-
mation of MTC and pheochromocytoma, but may not be
sufficient, as there are patients who have never developed
MTC or pheochromocytoma during their life or devel-
oped MTC late in their lifetime [3,4,31-33]. Here, we
detected somatic VHL gene alterations in 3 of 6 MTCs
from MEN2A patients and no somatic VHL gene altera-
tion in 1 patient with MEN2A and CCH. In addition, all 3
MTCs with LOH at the VHL gene also had allelic imbal-
ance of RET. However, in only one of these MTCs, a
somatic VHL mutation was found in addition to LOH at
the VHL gene. In our single case of CCH, no imbalance
between mutant and wild-type RET has been detected and
no somatic VHL gene alteration. Therefore, additional
somatic mutational events including the VHL gene may
be required to set off tumorigenesis in patients with RET
germline mutations. CCH foci have heterogeneous DNA
deletions including LOH of TP53, RB1, and WT1 [34].
Polymorphisms G691S/S904S of RET have recently been
found to affect the development of MTC and the age at
onset of MEN2A in patients with a RET germline mutation
[35-37]. Elisei et al. [36] found a statistically significant
higher allelic frequency of G691S polymorphism in MTCs
than that found in normal controls. Cebrian et al. [37]
carried out an association study in 135 sporadic MTC
patients and 533 controls and discovered a strong associ-
ation between the disease and specific haplotypes of RET.
Somatic RET mutations such as M918T in MTC or pheo-
chromocytoma of patients with a RET germline mutation
appear to represent a phenomenon of tumor progression
[38-43]. Chromosomal imbalances in MTC include dele-
tions of chromosomes 1p, 3q26.3-q27, 4, 9q13-q22, 13 q,
and 22q [24]. Marsh et al. [24] found loss of whole or par-
tial chromosome 3 including the region of the VHL locus
as the predominant imbalance (40% of cases). Biallelic
inactivation of VHL should lead to loss of VHL protein.
Using immunohistochemistry, VHL protein is detectable
in thyroid follicles and differentiated tumors derived from
follicular epithelium, but is weakly or not detectable in
nonneoplastic and neoplastic C cells [44]. Since, in our
study, neither allelic imbalance of RET nor somatic VHL
gene alterations occurred in the CCH specimen (presum-
ably the precursor lesion of MTC), we suggest that such
somatic VHL gene alterations rather play a role in tumor
progression than in tumor formation of MEN2-related
MTC. This interpretation is based on a single case of CCH
and would require confirmation in studies of larger size.
Conclusion
Tumor formation in these selected MEN 2A-related MTCs
may have occurred by first, a RET germline mutation,
leading to hyperplasia of C cells and second, an amplifica-
tion event of mutant RET which, however, could not be
consistently detected by the methods used by us (poly-
morphic marker analysis). Subsequent somatic VHL gene
deletion and mutation in selected C cells may lead to fur-
ther transformation and tumor progression. However,
given the small sample size, it is possible that tumor for-
mation and progression in a significant number of tumors
may occur by other mechanisms.
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